This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a particular treatment arm, dose expansion will assess the anti-tumor activity and further assess the safety, tolerability, and PK/PD of each regimen at the maximum tolerated dose / recommended dose or lower dose.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
344
Emory University School of Medicine-Winship Cancer Institute
Atlanta, Georgia, United States
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas, United States
Novartis Investigative Site
Melbourne, Victoria, Australia
Dose Escalation: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of monotherapy or combination treatment
A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle of treatment
Time frame: 21 days
Dose Escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
All information obtained on AE will be displayed by treatment group. Summary tables will include only AEs that started/worsened during the cycles of treatment (treatment-emergent AEs).
Time frame: 24 months
Dose Escalation: Frequency of dose interruptions and reductions, by treatment
Tolerability of study drug will be assessed by summarizing the number of and reason for dose delays and dose reductions.
Time frame: 24 months
Dose Escalation: Dose intensity by treatment
Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of treatment.
Time frame: 24 months
Dose Expansion: Overall response rate (ORR) per RECIST v1.1, by treatment
Overall response rate is defined as the proportion of patients with a BOR of CR or PR according to RECIST 1.1, and will be summarized along with the corresponding 95% exact binomial confidence interval (CI). Applies to all groups except the brain metastasis group.
Time frame: 24 months
Dose expansion: Overall intracranial response rate (OIRR) per mRANO-BM
OIRR per mRANO-BM is defined as the proportion of participants with a best overall intracranial response (BOIR) of CR or PR according to mRANO-BM criteria, and will be summarized along with the corresponding 90% and 95% exact CI. Applies to brain metastasis group only.
Time frame: 24 months
Dose expansion: Incidence and severity of AEs and SAEs
All information obtained on AE will be displayed by treatment group. Summary tables will include only AEs that started/worsened during the cycles of treatment (treatment-emergent AEs). Applies to JDQ443 dose randomization group only.
Time frame: 24 months
Dose expansion: frequency of dose interruptions and reductions, by treatment
Tolerability of study drug will be assessed by summarizing the number of and reason for dose delays and dose reductions. Applies to JDQ443 dose randomization group only.
Time frame: 24 months
Dose expansion: Dose intensity by treatment
Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of treatment. Applies to JDQ443 dose randomization group only
Time frame: 24 months
Dose expansion: ORR per RECIST 1.1 of JDQ443 single agent in patients with non-small cell lung cancer (JDQ443 dose randomization group only)
Overall response rate is defined as the proportion of patients with BOR of CR or PR according to RECIST 1.1, and will be summarized along with the corresponding 95% exact binomial confidence interval (CI). Applies to JDQ443 dose randomization group only
Time frame: 24 months
Dose Escalation and Expansion: ORR per RECIST v1.1
Overall response rate is defined as the proportion of patients with a BOR of CR or PR according to RECIST 1.1, and will be summarized along with the corresponding 95% exact binomial confidence interval (CI)
Time frame: 24 months
Dose Escalation and Expansion: Best Overall Response (BOR) per RECIST v1.1
BOR is defined as the best overall confirmed response recorded from the start of the treatment until disease progression/recurrence.
Time frame: 24 months
Dose Escalation and Expansion: Progression-free survival (PFS) per RECIST v1.1, Overall Survival (OS)
Per RECIST 1.1, PFS is defined as the time from the date of start of treatment to the date of the first documented progression, or death. If patient has not had an event, PFS will be censored at the date of last adequate tumor assessment. PFS will be summarized using the Kaplan-Meier method, along with 95% CI
Time frame: 24 months
Dose Escalation and Expansion: Duration of Response (DOR) per RECIST v1.1
Duration of response is defined as the time from the date of the first documented response (CR or PR), to the date of first documented progression, or death due any cause. Estimates will use Kaplan-Meier method, and median DOR and corresponding 95% CI will be presented.
Time frame: 24 months
Dose Escalation and Expansion: Disease Control Rate (DCR) per RECIST v1.1
The disease control rate is calculated as the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease. It will be summarized along with the corresponding 95% exact CI
Time frame: 24 months
Dose Escalation and Expansion: Plasma or serum concentration vs time profiles (AUC) by treatment
AUC is defined as area under the plasma or serum concentration versus time curve after a dose of JDQ443, TNO155 and tislelizumab
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Copenhagen, Denmark
...and 27 more locations
Time frame: Up to 24 months
Dose Escalation and Expansion: Plasma concentration (Cmax) by treatment
Cmax is defined as the maximum observed plasma or serum drug concentration after single dose administration.
Time frame: Up to 24 months
Dose Escalation and Expansion: Time to achieve Cmax (Tmax) by treatment
Tmax is defined as the time to reach maximum plasma or serum drug concentration after single dose administration.
Time frame: Up to 24 months
Dose Escalation and Expansion: Antidrug antibody (ADA) incidence by treatment
To evaluate the immunogenicity of tislelizumab when dosed in combination with JDQ443 and/or TNO155 - only applicable to Arms C and D
Time frame: Up to 24 months
Dose Expansion: Dose intensity by treatment
Time frame: 24 months
Dose Expansion: Frequency of dose interruptions and reductions, by treatment
Tolerability of study drug will be assessed by summarizing the number of and reason for dose delays and dose reductions.
Time frame: 24 months
Dose Expansion: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of monotherapy or combination treatment
A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle of treatment
Time frame: 21 days
Dose Expansion: Incidence and severity of AEs and SAEs by treatment
Time frame: 24 months
Dose expansion: Intracranial disease control rate (IDCR) per mRANO-BM
IDCR is the proportion of participants with a confirmed BOIR of CR or PR or SD (or non-CR/non-PD) per mRANO-BM criteria. It will be summarized along with the corresponding 90% and 95% CI. Applies to the brain metastasis group only.
Time frame: 24 months
Dose expansion: Best overall intracranial response (BOIR) per mRANO-BM
BOIR is defined as the best overall confirmed response recorded from the start of the treatment until disease progression/recurrence per mRANO-BM, or until patient comes off study, whichever comes first. BOIR will be summarized along with the corresponding 95% exact CI. Applies to the brain metastasis group only.
Time frame: 24 months
Dose expansion: Intracranial progression free survival (IPFS) per mRANO-BM
IPFS is defined as the time from the date of start of treatment to the date of the first documented progression per mRANO-BM, or death due to any cause. If a patient has not had an event, IPFS will be censored at the date of last adequate tumor assessment. IPFS will be summarized using the Kaplan-Meier method. Median IPFS and IPFS probability at pre specified time-points will be presented along with 95% CI. Applies to the brain metastasis group only.
Time frame: 24 months
Dose expansion: Duration of intracranial response (DOIR) per mRANO-BM
DOIR is defined as the time from the date of first documented intracranial response of either CR or PR to the date of the first documented intracranial progression as per mRANO-BM criteria as assessed by central review or date of death due to underlying cause of cancer. DOIR will be summarized using the KM method if data permit. Median DOIR, with corresponding 95% CI. KM estimates for DOIR proportions at specific time points, along with 95% CI will also be provided. Applies to the brain metastasis group only.
Time frame: 24 months